Literature DB >> 34824448

Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.

Kosei Nakajima1,2, Yoshinori Ino1,2, Chie Naito1,2, Satoshi Nara3, Mari Shimasaki1,2, Utako Ishimoto1,2, Toshimitsu Iwasaki1,2,3, Noriteru Doi1,2, Minoru Esaki3, Yoji Kishi3, Kazuaki Shimada3, Nobuyoshi Hiraoka4,5.   

Abstract

BACKGROUND: The treatment of pancreatic cancer (PDAC) remains clinically challenging, and neoadjuvant therapy (NAT) offers down staging and improved surgical resectability. Abundant fibrous stroma is involved in malignant characteristic of PDAC. We aimed to investigate tissue remodelling, particularly the alteration of the collagen architecture of the PDAC microenvironment by NAT.
METHODS: We analysed the alteration of collagen and gene expression profiles in PDAC tissues after NAT. Additionally, we examined the biological role of Ephrin-A5 using primary cultured cancer-associated fibroblasts (CAFs).
RESULTS: The expression of type I, III, IV, and V collagen was reduced in PDAC tissues after effective NAT. The bioinformatics approach provided comprehensive insights into NAT-induced matrix remodelling, which showed Ephrin-A signalling as a likely pathway and Ephrin-A5 (encoded by EFNA5) as a crucial ligand. Effective NAT reduced the number of Ephrin-A5+ cells, which were mainly CAFs; this inversely correlated with the clinical tumour shrinkage rate. Experimental exposure to radiation and chemotherapeutic agents suppressed proliferation, EFNA5 expression, and collagen synthesis in CAFs. Forced EFNA5 expression altered CAF collagen gene profiles similar to those found in PDAC tissues after NAT.
CONCLUSION: These results suggest that effective NAT changes the extracellular matrix with collagen profiles through CAFs and their Ephrin-A5 expression.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34824448      PMCID: PMC8854423          DOI: 10.1038/s41416-021-01639-9

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  41 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Ducreux; A Sa Cuhna; C Caramella; A Hollebecque; P Burtin; D Goéré; T Seufferlein; K Haustermans; J L Van Laethem; T Conroy; D Arnold
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

3.  Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.

Authors:  Yuki Homma; Koichi Taniguchi; Takashi Murakami; Kazuya Nakagawa; Masatoshi Nakazawa; Ryusei Matsuyama; Ryutaro Mori; Kazuhisa Takeda; Michio Ueda; Yasushi Ichikawa; Kuniya Tanaka; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2013-12-06       Impact factor: 5.344

Review 4.  Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials.

Authors:  M Mura Assifi; Xuyang Lu; Guido Eibl; Howard A Reber; Gang Li; O Joe Hines
Journal:  Surgery       Date:  2011-09       Impact factor: 3.982

5.  NCCN Guidelines Updates: Pancreatic Cancer.

Authors:  Margaret A Tempero
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

6.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-08       Impact factor: 11.908

7.  Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.

Authors:  Takashi Murakami; Yuki Homma; Ryusei Matsuyama; Ryutaro Mori; Kentaro Miyake; Yusaku Tanaka; Kanechika Den; Yoji Nagashima; Masatoshi Nakazawa; Yukihiko Hiroshima; Michio Ueda; Kuniya Tanaka; Robert M Hoffman; Michael Bouvet; Itaru Endo
Journal:  J Surg Oncol       Date:  2017-06-12       Impact factor: 3.454

8.  Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.

Authors:  Reza Nejati; Jennifer B Goldstein; Daniel M Halperin; Hua Wang; Nazila Hejazi; Asif Rashid; Matthew H Katz; Jeffrey E Lee; Jason B Fleming; Jaime Rodriguez-Canales; Jorge Blando; Ignacio I Wistuba; Anirban Maitra; Robert A Wolff; Gauri R Varadhachary; Huamin Wang
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 9.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

10.  Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.

Authors:  Shintaro Takeuchi; Muhammad Baghdadi; Takahiro Tsuchikawa; Haruka Wada; Toru Nakamura; Hirotake Abe; Sayaka Nakanishi; Yuu Usui; Kohtaro Higuchi; Mizuna Takahashi; Kazuho Inoko; Syoki Sato; Hironobu Takano; Toshiaki Shichinohe; Ken-ichiro Seino; Satoshi Hirano
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

View more
  3 in total

1.  Ephrin B Activate Src Family Kinases in Fibroblasts Inducing Stromal Remodeling in Prostate Cancer.

Authors:  Mamatha Kakarla; Sathyavathi ChallaSivaKanaka; Mary F Dufficy; Victoria Gil; Yana Filipovich; Renee Vickman; Susan E Crawford; Simon W Hayward; Omar E Franco
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

2.  Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma.

Authors:  Ulrike Heger; Anna Martens; Lisa Schillings; Britta Walter; Domenic Hartmann; Ulf Hinz; Thomas Pausch; Nathalia Giese; Christoph W Michalski; Thilo Hackert
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

Review 3.  Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.

Authors:  Huiru Zhang; Longyun Ye; Xianjun Yu; Kaizhou Jin; Weiding Wu
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.